1822 related articles for article (PubMed ID: 17288696)
1. Resource utilization in asthma: combined fluticasone propionate/salmeterol compared with inhaled corticosteroids.
Friedman HS; Yawn BP
Curr Med Res Opin; 2007 Feb; 23(2):427-34. PubMed ID: 17288696
[TBL] [Abstract][Full Text] [Related]
2. Effects of fluticasone propionate/salmeterol combination on asthma-related health care resource utilization and costs and adherence in children and adults with asthma.
Delea TE; Hagiwara M; Stanford RH; Stempel DA
Clin Ther; 2008 Mar; 30(3):560-71. PubMed ID: 18405796
[TBL] [Abstract][Full Text] [Related]
3. Retrospective claims study of fluticasone propionate/salmeterol fixed-dose combination use as initial asthma controller therapy in children despite guideline recommendations.
Friedman HS; Eid NS; Crespi S; Wilcox TK; Reardon G
Clin Ther; 2009 May; 31(5):1056-63. PubMed ID: 19539106
[TBL] [Abstract][Full Text] [Related]
4. Resource utilization with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies in children with asthma.
Stempel DA; Riedel AA; Carranza Rosenzweig JR
Curr Med Res Opin; 2006 Mar; 22(3):463-70. PubMed ID: 16574030
[TBL] [Abstract][Full Text] [Related]
5. Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs.
O'Connor RD; Stanford R; Crim C; Yancey SW; Edwards L; Rickard KA; Dorinsky P
Ann Allergy Asthma Immunol; 2004 Dec; 93(6):581-8. PubMed ID: 15609769
[TBL] [Abstract][Full Text] [Related]
6. Mometasone furoate vs fluticasone propionate with salmeterol: multivariate analysis of resource use and asthma-related charges.
Navaratnam P; Friedman HS; Urdaneta E
Curr Med Res Opin; 2009 Dec; 25(12):2895-901. PubMed ID: 19821655
[TBL] [Abstract][Full Text] [Related]
7. Costs and resource use of mild persistent asthma patients initiated on controller therapy.
Colice GL; Yu AP; Ivanova JI; Hsieh M; Birnbaum HG; Lage MJ; Brewster C
J Asthma; 2008 May; 45(4):293-9. PubMed ID: 18446593
[TBL] [Abstract][Full Text] [Related]
8. Risk of asthma exacerbation, asthma-related health care utilization and costs, and adherence to controller therapy in patients with asthma receiving fluticasone propionate/salmeterol inhalation powder 100 μg/50 μg versus mometasone furoate inhalation powder.
Hagiwara M; Delea TE; Stanford RH
J Asthma; 2013 Apr; 50(3):287-95. PubMed ID: 23305687
[TBL] [Abstract][Full Text] [Related]
9. Does measuring BHR add to guideline derived clinical measures in determining treatment for patients with persistent asthma?
Koenig SM; Murray JJ; Wolfe J; Andersen L; Yancey S; Prillaman B; Stauffer J; Dorinsky P
Respir Med; 2008 May; 102(5):665-73. PubMed ID: 18328683
[TBL] [Abstract][Full Text] [Related]
10. Appropriate use of inhaled corticosteroid and long-acting beta(2)-adrenergic agonist combination therapy among asthma patients in a US commercially insured population.
Ye X; Gutierrez B; Zarotsky V; Nelson M; Blanchette CM
Curr Med Res Opin; 2009 Sep; 25(9):2251-8. PubMed ID: 19622006
[TBL] [Abstract][Full Text] [Related]
11. Association between previous health care use and initiation of inhaled corticosteroid and long-acting beta2-adrenergic agonist combination therapy among US patients with asthma.
Blanchette CM; Culler SD; Ershoff D; Gutierrez B
Clin Ther; 2009 Nov; 31(11):2574-83. PubMed ID: 20110003
[TBL] [Abstract][Full Text] [Related]
12. Effect of combination fluticasone propionate and salmeterol or inhaled corticosteroids on asthma-related outcomes in a Medicare-eligible population.
Stanford RH; Blanchette CM; Roberts MH; Petersen H; Fuhlbrigge AL
Am J Geriatr Pharmacother; 2012 Dec; 10(6):343-51. PubMed ID: 23083688
[TBL] [Abstract][Full Text] [Related]
13. Inhaled corticosteroids vs leukotriene receptor antagonists: health care costs across varying asthma severities.
O'Connor RD; Parasuraman B; Roberts C; Leibman C
Ann Allergy Asthma Immunol; 2006 Aug; 97(2):236-43. PubMed ID: 16937758
[TBL] [Abstract][Full Text] [Related]
14. Comparison of prevalence, cost, and outcomes of a combination of salmeterol and fluticasone therapy to common asthma treatments.
Wang SW; Liu X; Wiener DJ; Sennett C; Bowers BW; Legorreta AP
Am J Manag Care; 2001 Sep; 7(9):913-22. PubMed ID: 11570024
[TBL] [Abstract][Full Text] [Related]
15. Asthma hospitalization risk and costs for patients treated with fluticasone propionate vs montelukast.
Orsini L; Limpa-Amara S; Crown WH; Stanford RH; Kamal K
Ann Allergy Asthma Immunol; 2004 May; 92(5):523-9. PubMed ID: 15191020
[TBL] [Abstract][Full Text] [Related]
16. Outcomes and costs of patients with persistent asthma treated with beclomethasone dipropionate hydrofluoroalkane or fluticasone propionate.
Lage MJ; Gross GN; Brewster C; Spalitto A
Adv Ther; 2009 Aug; 26(8):762-75. PubMed ID: 19669630
[TBL] [Abstract][Full Text] [Related]
17. Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma.
Masoli M; Weatherall M; Holt S; Beasley R
Thorax; 2005 Sep; 60(9):730-4. PubMed ID: 16135679
[TBL] [Abstract][Full Text] [Related]
18. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies.
Stoloff SW; Stempel DA; Meyer J; Stanford RH; Carranza Rosenzweig JR
J Allergy Clin Immunol; 2004 Feb; 113(2):245-51. PubMed ID: 14767437
[TBL] [Abstract][Full Text] [Related]
19. Retrospective comparison of early versus late treatment with fluticasone propionate/salmeterol after an asthma exacerbation.
Hagiwara M; Delea TE; Stanford RH
J Asthma; 2011 Sep; 48(7):721-8. PubMed ID: 21793768
[TBL] [Abstract][Full Text] [Related]
20. Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen.
Rascati KL; Akazawa M; Johnsrud M; Stanford RH; Blanchette CM
Clin Ther; 2007 Jun; 29(6):1203-13. PubMed ID: 17692734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
